DeepCyte

Cover Block

PUBLIC

Attribute	Detail
Company Name	DeepCyte
Tagline	AI toxicology platform combining single-cell metabolomics to predict and explain drug toxicity in human cells.
Headquarters	Delaware, US; Copenhagen, Denmark
Founded	2025
Stage	Seed
Business Model	B2B
Industry	Deeptech
Technology	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding Label	Seed (total disclosed ~$1,500,000)

Links

PUBLIC

• Website: https://www.deepcyte.bio
• LinkedIn: https://www.linkedin.com/company/deepcyte

Executive Summary

PUBLIC DeepCyte is a newly launched techbio startup applying single-cell metabolomics and AI to predict drug toxicity, a proposition that merits investor attention for its potential to address a costly and persistent bottleneck in biopharma development [PR Newswire, April 2026]. The company was founded in 2025 by Theodore Alexandrov, a metabolomics researcher whose academic work has focused on spatial and single-cell analysis, and Gina Wallbank, who serves as CTO [Deep Tech Week, 2026] [LinkedIn, 2026]. Its core offering integrates two proprietary components: MetaCore, a high-throughput single-cell metabolomics platform, and DeeImmuno, an AI model trained to detect metabolic changes in individual immune cells, predict toxicity class, and infer biological mechanisms [The SaaS News, 2026] [PR Newswire, 2026]. This approach differentiates from traditional animal models and bulk assays by providing human-centric, cell-specific readouts earlier in the drug discovery pipeline, with an initial focus on oncology and immunology therapeutics [DeepCyte, 2026]. The company has secured $1.5 million in seed funding, with medtech executive and investor Carl J. G. Evertsz serving as the lead backer and Chairman of the Board [PR Newswire, April 2026] [The SaaS News, 2026]. Over the next 12-18 months, key milestones to watch will be the validation of DeeImmuno with pharmaceutical partners, the publication of peer-reviewed performance data, and the expansion of the commercial team to convert scientific promise into contracted revenue. Data Accuracy: GREEN -- Confirmed by PR Newswire, The SaaS News, Crunchbase, and LinkedIn.

Taxonomy Snapshot

Axis	Value
Stage	Seed
Business Model	B2B
Industry / Vertical	Deeptech
Technology Type	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding	Seed (total disclosed ~$1,500,000)

Company Overview

PUBLIC

DeepCyte launched publicly in April 2026 with a $1.5 million seed round, positioning itself as a techbio startup at the intersection of single-cell biology and AI [PR Newswire, April 2026]. The company is legally incorporated in Delaware, US, and maintains a research and operational presence in Copenhagen, Denmark, reflecting its academic and biotech roots [Crunchbase, 2026]. Its founding story is centered on translating foundational research in spatial and single-cell metabolomics into a commercial platform for predictive toxicology.

The founding team is led by CEO Theodore Alexandrov, Ph.D., an academic researcher with a documented focus on metabolomics and single-cell analysis [LinkedIn, 2026]. His scientific contributions include the development of METASPACE, an open-source platform for spatial metabolomics, and SpaceM, a method for spatial single-cell metabolomics, work that has led to over 100 publications and several patents [LiverSeminars, 2026]. Co-founder Gina Wallbank is identified as the company's Chief Technology Officer [Deep Tech Week, 2026]. The company's initial capital and strategic guidance come from Carl J. G. Evertsz, a medtech executive and investor who led the seed round and serves as Chairman of the Board [The SaaS News, 2026].

Key milestones are concentrated in 2026, beginning with the company's formal launch and funding announcement in April. The concurrent introduction of its two core product components, the MetaCore metabolomics platform and the DeeImmuno AI model, established its initial commercial proposition [PR Newswire, April 2026]. Prior to this launch, the underlying technology was developed within Alexandrov's academic research group, with public scientific contributions dating back several years [ResearchGate, 2026].

Data Accuracy: GREEN -- Confirmed by multiple public press releases and corporate profiles.

Product and Technology

MIXED

DeepCyte’s product architecture is a two-part system designed to move toxicology testing earlier and deeper into the drug development pipeline. The company’s core offering integrates a proprietary hardware-enabled data generation platform with a purpose-built AI analytics layer, a structure that seeks to control both the quality of the input data and the sophistication of the output predictions [DeepCyte, retrieved 2026].

• MetaCore: Single-cell metabolomics data. The foundational layer is MetaCore, described as a “high-throughput single-cell metabolomics platform” that uses MALDI mass spectrometry to map cellular metabolism at scale [PR Newswire, April 2026]. This platform generates the unique dataset,metabolic profiles of individual human cells,that feeds the company’s AI models. The emphasis on single-cell resolution and metabolic readouts is a direct challenge to traditional bulk assays and animal models, which the company argues mask cell-to-cell heterogeneity and are physiologically distant from human biology [DeepCyte, retrieved 2026].

• DeeImmuno: AI toxicology analysis. The analytical engine is DeeImmuno, an AI model trained on proprietary single-cell metabolomics atlases derived from MetaCore [PR Newswire, retrieved 2026]. It is designed to detect metabolic changes in individual immune cells to evaluate drug toxicity, predict its class, identify relevant biomarkers, and infer biological mechanisms [Preqin, retrieved 2026] [PR Newswire, retrieved 2026]. The initial focus is on immunology and oncology, therapeutic areas where precise, mechanistic understanding of off-target effects is particularly valuable [LinkedIn, retrieved 2026].

The product’s commercial wedge appears to be its closed-loop integration. By owning the end-to-end process from wet-lab sample processing to AI-driven insight, DeepCyte aims to offer a service that is both differentiated in its scientific depth and defensible through accumulated proprietary data. The public positioning is exclusively as a tool for biopharma partners, with no mention of a standalone software product for direct customer use [The SaaS News, retrieved 2026] [ContractResearchMap, retrieved 2026].

Data Accuracy: YELLOW -- Product claims are consistent across company and press materials, but technical performance benchmarks and customer validation cases are not publicly available.

Market Research

PUBLIC The push to de-risk drug development is accelerating, and the market for tools that can predict failure earlier is expanding beyond traditional preclinical models. DeepCyte operates at the intersection of two high-growth sectors: AI-powered drug discovery and advanced in vitro toxicology. While the company's specific total addressable market is not quantified in public disclosures, its value proposition targets the substantial and persistent costs of late-stage clinical trial failures attributed to safety issues.

Demand is driven by the pharmaceutical industry's need to reduce both financial losses and development timelines. The high cost of bringing a drug to market, often cited at over $2 billion, is heavily weighted by failures in Phase II and III trials, where toxicity is a leading cause of attrition [Nature Reviews Drug Discovery]. This creates a clear economic incentive for more predictive human-relevant models earlier in the pipeline. Concurrent tailwinds include regulatory shifts, such as the FDA Modernization Act 2.0, which explicitly allows for the use of alternative non-animal testing methods, and growing ethical and scientific scrutiny of animal model translatability [FDA].

Adjacent and substitute markets provide context for DeepCyte's potential scale. The broader AI in drug discovery market is projected to reach $4.9 billion by 2028, according to a Grand View Research report cited in industry coverage [Grand View Research, 2024]. More directly, the preclinical toxicology testing market itself is a multi-billion dollar segment. DeepCyte's single-cell metabolomics approach positions it as a potential premium alternative within this space, aiming to displace portions of both traditional animal testing budgets and less granular in vitro assay spend.

Key regulatory and macro forces are broadly supportive but introduce execution complexity. The move towards precision medicine, particularly in oncology and immunology where DeepCyte is focused, demands more nuanced safety profiling that accounts for patient heterogeneity, a challenge bulk assays cannot address. However, adoption hinges on demonstrating clinical concordance,proving that predictions made in a dish correlate with human outcomes. This validation burden is significant and will require extensive partnership data with pharmaceutical companies to overcome.

Market Segment	Reported Size	Source	Notes
AI in Drug Discovery	$4.9B (by 2028)	[Grand View Research, 2024]	Analogous growth market for enabling technologies.
Preclinical Toxicology Testing	Multi-billion dollar	Industry standard	DeepCyte's core substitute market.

This sizing context suggests DeepCyte is entering a validated and growing arena, but one where its specific wedge,single-cell metabolomics for toxicity,remains a nascent, unproven commercial category. The company's success will be less about capturing a share of a generic AI market and more about defining and owning a new sub-segment within preclinical safety.

Data Accuracy: YELLOW -- Market sizing is drawn from analogous, third-party industry reports; specific TAM for single-cell AI toxicology is not publicly defined.

Competitive Landscape

MIXED DeepCyte enters a crowded field of drug safety testing by claiming a unique position at the intersection of single-cell metabolomics and AI-driven toxicology. Its primary competition is not a single entity but a fragmented set of incumbents and challengers across different layers of the value chain.

A direct, named competitor to DeepCyte's integrated platform is not cited in public sources, making a formal comparison table impossible. The competitive map must instead be drawn from the categories of services and technologies the company positions itself against.

• Incumbent service providers. The most direct substitutes are large contract research organizations (CROs) like Charles River Laboratories and Labcorp, which offer traditional in vivo toxicology studies and in vitro assays [PUBLIC]. These incumbents own the dominant share of outsourced preclinical safety spending and have established client relationships. Their advantage is scale and regulatory acceptance; their weakness is the very reliance on animal models and bulk cell assays that DeepCyte criticizes.
• Specialized challengers. A newer wave of companies applies computational biology to de-risk drug development. Firms like Recursion Pharmaceuticals and Insitro use high-content cellular imaging and machine learning for phenotypic drug discovery, which can include toxicity signals [PUBLIC]. Their focus is broader than toxicology, but they compete for the same biopharma budget and mindshare around AI-driven preclinical insights.
• Adjacent technology vendors. DeepCyte's MetaCore platform, as a single-cell metabolomics tool, competes with instrumentation and software from vendors like Bruker (for MALDI mass spectrometry) and 10x Genomics (for single-cell genomics) [PUBLIC]. These companies provide the enabling hardware and analysis suites but typically do not offer the finished, application-specific AI toxicology service that DeeImmuno represents.

DeepCyte's defensible edge today rests almost entirely on its proprietary data and scientific founder's expertise. The company's AI model, DeeImmuno, is trained on "proprietary single-cell metabolomics atlases" generated by its MetaCore platform [PR Newswire, April 2026]. This creates a data moat; replicating such a specialized dataset would require significant capital and time. The edge is durable if the company can continue to generate novel, high-quality data that improves model performance, but it is perishable if a well-funded competitor acquires similar data through partnership or internal effort.

The exposure is most acute in commercial distribution and clinical validation. DeepCyte lacks the sales footprint of a major CRO and the brand recognition of a public AI biotech. A competitor like Recursion, with its established platform and partnership with Bayer, could theoretically develop or acquire a competing single-cell toxicology module, leveraging its existing commercial channel [PUBLIC]. Furthermore, DeepCyte's approach, while scientifically compelling, must still prove it can meet the stringent regulatory standards for preclinical safety data that animal studies currently satisfy.

The most plausible 18-month scenario is one of niche establishment versus broader platform encroachment. If DeepCyte successfully lands a flagship partnership with a top-20 pharma company to validate its approach, it becomes the "winner" in carving out a defensible niche as the go-to for single-cell metabolic toxicology. The "loser" in this case would be smaller CROs still reliant on commoditized, low-margin in vitro toxicology services, which could see their value proposition further eroded. Conversely, if validation stalls and a larger AI-driven drug discovery platform simply adds a competent metabolomics toxicity module, DeepCyte risks being relegated to a technology vendor or being acquired for its IP.

Data Accuracy: YELLOW -- Competitive analysis is inferred from the company's stated positioning against animal models and bulk assays; no direct competitors are named in captured sources.

Opportunity

PUBLIC If DeepCyte can successfully translate its single-cell metabolomics and AI platform into a new standard for predictive toxicology, the company could capture a significant portion of the multi-billion dollar drug safety testing market by offering a more precise, human-centric alternative to legacy methods.

The headline opportunity for DeepCyte is to become the category-defining platform for cell-specific, mechanism-aware toxicology in biopharma. This outcome is reachable because the company is not just applying AI to existing data types, but is vertically integrating a proprietary data generation engine, MetaCore, with a purpose-built AI model, DeeImmuno [PR Newswire, retrieved 2026]. The core promise is to move toxicology from a late-stage, often animal-dependent bottleneck to an earlier, more informative part of the drug development process [DeepCyte, retrieved 2026]. Success here would position DeepCyte not as a simple service provider, but as the source of a new, higher-fidelity data layer for drug safety, a critical and expensive pain point for pharmaceutical R&D.

Growth could follow several distinct, concrete paths. The company's initial focus on oncology and immunology precision therapeutics provides a clear beachhead [LinkedIn, retrieved 2026].

Scenario	What happens	Catalyst	Why it's plausible
Platform Adoption	Biopharma partners integrate MetaCore and DeeImmuno as a standard in-vitro toxicology screen for early-stage assets.	A landmark publication or a partnership with a top-20 pharma company validating the platform's predictive power against clinical outcomes.	The founder's extensive academic track record in spatial and single-cell omics, including over 100 publications and prior startup experience, provides a credible foundation for scientific validation [LiverSeminars, retrieved 2026].
Regulatory Pathway	The company's single-cell metabolic signatures become accepted biomarkers for specific toxicity endpoints by regulatory bodies.	Successful completion of a regulatory-grade study submitted to the FDA or EMA as part of a partner's Investigational New Drug (IND) application.	The explicit positioning against animal models and bulk assays aligns with a broader industry and regulatory push toward human-relevant testing methodologies [DeepCyte, retrieved 2026].

Compounding for DeepCyte would manifest as a data and scientific credibility flywheel. Each new partnership or study run on the MetaCore platform would generate proprietary, single-cell metabolomics data tied to specific compounds and toxicity outcomes. This expanding dataset would, in turn, improve the predictive accuracy and mechanistic insight of the DeeImmuno AI model, creating a performance gap that competitors without equivalent data access would struggle to close [PR Newswire, retrieved 2026]. Early validation from respected pharmaceutical partners would also build the company's reputation, lowering the barrier to adoption with subsequent customers.

Quantifying the size of the win is challenging for a pre-revenue platform, but credible comparables exist. Publicly traded contract research organizations (CROs) focused on specialized preclinical services, such as Charles River Laboratories, trade at enterprise values reflecting the critical nature of their work in the drug development pipeline. A more direct, though private, comparable might be a company like Recursion Pharmaceuticals, which built its valuation on a platform combining cellular imaging and AI for drug discovery. If DeepCyte executes on its platform adoption scenario and captures even a single-digit percentage of the global preclinical toxicology testing market, the outcome could support a valuation in the hundreds of millions of dollars (scenario, not a forecast). The recent $1.5 million seed round, while modest, provides the initial capital to begin generating the proof-of-concept data needed to pursue these paths [Preqin, April 2026].

Data Accuracy: YELLOW -- The opportunity analysis is based on the company's stated positioning and the founder's publicly documented scientific background. Market size and valuation comparables are inferred from the broader industry context rather than specific, cited projections for DeepCyte.

Sources

PUBLIC

1. [PR Newswire, April 2026] DeepCyte raises $1.5M to bring single-cell AI toxicology to drug development | https://www.prnewswire.com/news-releases/deepcyte-raises-1-5m-to-bring-single-cell-ai-toxicology-to-drug-development-302737632.html

2. [The SaaS News, 2026] DeepCyte Raises $1.5M Seed Round | https://www.thesaasnews.com/news/deepcyte-raises-1-5m-seed-round

3. [Crunchbase, 2026] DeepCyte - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/deepcyte

4. [LinkedIn, 2026] DeepCyte | https://www.linkedin.com/company/deepcyte

5. [DeepCyte, 2026] DeepCyte | https://www.deepcyte.bio

6. [Preqin, 2026] DeepCyte Inc. | Preqin | https://www.preqin.com/data/profile/asset/deepcyte-inc-/796976

7. [Deep Tech Week, 2026] Deep Tech Week | https://www.deeptechweek.com

8. [LiverSeminars, 2026] LiverSeminars | https://www.liverseminars.com

9. [ResearchGate, 2026] ResearchGate | https://www.researchgate.net

10. [ContractResearchMap, 2026] DeepCyte | ContractResearchMap | https://www.contractresearchmap.com/providers/deepcyte

11. [Nature Reviews Drug Discovery] Nature Reviews Drug Discovery | https://www.nature.com/articles/nrd.2016.230

12. [FDA] FDA Modernization Act 2.0 | https://www.fda.gov

13. [Grand View Research, 2024] AI in Drug Discovery Market Size Report, 2021-2028 | https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-ai-in-drug-discovery-market